ArticleWorld journal of surgical oncology2026
Percutaneous thermal ablation-based locoregional treatment for hepatocellular carcinoma larger than 3 cm: a 10-year single-center retrospective study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo investigate the long-term efficacy of percutaneous thermal ablation (PTA)-based locoregional treatment of patients with hepatocellular carcinoma (HCC) bearing tumors > 3 cm.
methodsIn this single-center, retrospective study of 359 HCC patients with 587 tumors (5.1 ± 0.021 cm) treated with PTA-based locoregional treatment between 2011 and 2021 was performed. Radiological response was evaluated per lesion on enhanced computed tomography imaging one month after ablation. Local tumor progression (LTP), regional recurrence (RR), disease-free survival (DFS) and overall survival (OS) rates were assessed per patient in follow-up, while a Cox hazards regression analysis was used to determine significant factors associated with OS and DFS. Therapeutic outcomes were assessed in a subgroup analysis of tumor size, number, and the patients’ age after propensity score matching.
resultsThe mean ± SD follow up duration was 30.0 ± 22.1 months. Complete Response was achieved in 87.7% of lesions after treatment. LTP and RR were detected in 52.5% and 66.9% of patients, respectively. The 1-, 3-, and 5-year DFS rates were 43.8%, 23.8%, and 14.6%, respectively. The 1-, 3-, 5-, 7-, and 10-year OS rates were 81.3%, 47.0%, 20.7%, 16.7%, and 14.4%, respectively. According to the multivariate analysis, tumor number, cirrhosis and platelet were significant factors for OS (P < 0.05); while tumor number and size were associated with DFS. In the subgroup analysis, the cumulative OS rates at 1, 3, and 5 years were 80.1%, 39.5%, and 27.1% in the medium tumor group(3 cm ≤ diameter < 5 cm) and 66.7%, 37.1%, and 7.3%, respectively, in the large tumor group (diameter ≥ 5 cm, HR = 1.44, 95% CI: 1.0–2.1, P < 0.05). The cumulative RR rates at 1, 3, and 5 years were 62.8%, 84%, and 89.3%, respectively, in the multiple-lesion group and 45.0%, 66.9%, and 76.6%, respectively, in the single-lesion group (HR = 0.63, 95% CI: 0.46–0.86, P < 0.05). The 1-, 3-, and 5-year OS rates were 71.5%, 34.9%, and 16.6% in patients aged ≤ 50 years and 83%, 50.4%, and 30.2%, respectively, in patients aged > 50 years (P < 0.05).
conclusionsPTA-based locoregional therapy represents an alternative method for the treatment of HCC patients with medium/large tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.